An Open-label, Multi-center Study to Evaluate the Pharmacokinetics, Safety, and Preliminary Efficacy of Isatuximab in Chinese Patients With Relapsed and/or Refractory Multiple Myeloma
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 16 Oct 2019
Price : $35 *
At a glance
- Drugs Isatuximab (Primary)
- Indications Multiple myeloma
- Focus Pharmacokinetics
- Sponsors Sanofi
- 24 Sep 2019 Planned End Date changed from 1 Aug 2021 to 1 Sep 2021.
- 24 Sep 2019 Status changed from recruiting to active, no longer recruiting.
- 18 Jul 2019 Planned End Date changed from 2 May 2022 to 1 Aug 2021.